This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Kolltan Pharmaceuticals raises $8.5mm in Series B round
Kolltan Pharmaceuticals (oncology therapeutics start-up) has raised $8.5mm through the sale of Series B convertible preferred shares to an affiliate of private equity firm Celtic Therapeutics Holdings LLLP (lead) and Tichenor Ventures LLC. The company could add another $1.5mm to this amount should the Celtic affiliate exercise a product development option. Kolltan, founded in 2007, raised $40mm through a Series A round completed in August of last year.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?